Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WISPER: Semaglutide in ER-positive Breast Cancer
NCT07909889Phase 2Not yet recruiting
- Sponsor
- Aarhus University Hospital
- Start
- Mar 2027
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Completion of the 26-week semaglutide treatment phase meeting all composite feasibility criteria. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07909889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909889.